Health and Healthcare

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

185 Articles

Trey Thoelcke | Jul 14, 2016 at 12:20 PM EDT

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

Lucky for Teva Pharmaceuticals, interest rates on all kinds of debt have never been lower in recorded human history, and…

Paul Ausick | Jun 24, 2016 at 4:04 PM EDT

British Banks Top Friday’s 52-Week Low Club

June 24, 2016: Here are four stocks trading with heavy volume among 119 equities making new 52-week lows in Friday’s…

Paul Ausick | Jun 23, 2016 at 4:04 PM EDT

Valeant Returns in Thursday’s 52-Week Low Club

June 23, 2016: Here are four stocks trading with relatively heavy volume among 18 equities making new 52-week lows in…

Paul Ausick | Jun 21, 2016 at 3:04 PM EDT

JetBlue Joins Valeant in Tuesday’s 52-Week Low Club

June 21, 2016: Here are four stocks trading with relatively heavy volume among 50 equities making new 52-week lows in…

Paul Ausick | Jun 20, 2016 at 4:04 PM EDT

Valeant Once More Makes Monday’s 52-Week Low Club

June 20, 2016: Here are four stocks trading with relatively heavy volume among 20 equities making new 52-week lows in…

Lee Jackson | Jun 19, 2016 at 10:05 AM EDT

Buffett and Top Hedge Funds Continue Massive Insider Buying: Phillips 66, Advanced Auto Parts, Lands’ End, Valeant Pharmaceuticals and More

With second-quarter earnings right around the corner, you can bet many of the corporate executives and 10% owners are looking…

Paul Ausick | Jun 17, 2016 at 4:04 PM EDT

Valeant, American Airlines Repeat in Friday’s 52-Week Low Club

June 17, 2016: Here are four stocks trading with relatively heavy volume among 36 equities making new 52-week lows in…

Paul Ausick | Jun 16, 2016 at 4:04 PM EDT

Valeant, American Airlines, Cavium in Thursday’s 52-Week Low Club

June 16, 2016: Here are four stocks trading with relatively heavy volume among 74 equities making new 52-week lows in Thursday’s…

Chris Lange | Jun 12, 2016 at 10:20 AM EDT

7 Biopharma Companies That Destroyed Shareholders Last Week

Biotech companies that lost their way last week truly burned shareholders, whether it was due to ASCO, earnings or even…

Chris Lange | Jun 9, 2016 at 9:40 AM EDT

Do Analysts See an Inflection Point in Valeant Pharmaceuticals After Earnings?

Despite its track record, some analysts are calling for an inflection point, while others are taking a relatively neutral stance…

Paul Ausick | Jun 7, 2016 at 4:04 PM EDT

The 52-Week Low Club for Tuesday

June 7, 2016: Here are four stocks trading with relatively heavy volume among 13 equities making new 52-week lows in…

Chris Lange | Jun 7, 2016 at 10:20 AM EDT

Why Earnings Were Not the Biggest Disappointment in Valeant’s Report

Valeant Pharmaceuticals International reported disappointing first-quarter financial results before the markets opened on Tuesday.

Chris Lange | Jun 5, 2016 at 9:55 AM EDT

The 3 Most Important Earnings of the Coming Week

24/7 Wall St. has put together a preview of Lululemon Athletica and a few other major companies reporting their quarterly…

Trey Thoelcke | May 26, 2016 at 9:35 AM EDT

Capital Infusions Are More Evidence of a Biotech Turnaround

Here are four biotech companies that have just either closed fresh financing rounds or issued IPOs that exceeded price expectations.

Chris Lange | May 16, 2016 at 10:25 AM EDT

Did Valeant Pharmaceuticals Capitulate Its Pricing?

Valeant Pharmaceuticals is trying to change its tune by announcing that it will offer an enhanced rebate program to all…

1 … 4 5 6 7 8 … 13

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

British Banks Top Friday’s 52-Week Low Club

Valeant Returns in Thursday’s 52-Week Low Club

JetBlue Joins Valeant in Tuesday’s 52-Week Low Club

Valeant Once More Makes Monday’s 52-Week Low Club

Buffett and Top Hedge Funds Continue Massive Insider Buying: Phillips 66, Advanced Auto Parts, Lands’ End, Valeant Pharmaceuticals and More

Valeant, American Airlines Repeat in Friday’s 52-Week Low Club

Valeant, American Airlines, Cavium in Thursday’s 52-Week Low Club

7 Biopharma Companies That Destroyed Shareholders Last Week

Do Analysts See an Inflection Point in Valeant Pharmaceuticals After Earnings?

The 52-Week Low Club for Tuesday

Why Earnings Were Not the Biggest Disappointment in Valeant’s Report

The 3 Most Important Earnings of the Coming Week

Capital Infusions Are More Evidence of a Biotech Turnaround

Did Valeant Pharmaceuticals Capitulate Its Pricing?

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

“Did you buy It from the mob?”: Dave Ramsey hosts floored by 21-year-old’s 30% truck loan

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan

Ripple’s $1.25 Billion Hidden Road Acquisition: One Year On, What’s Changed?

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

Why Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate

British Banks Top Friday’s 52-Week Low Club

Valeant Returns in Thursday’s 52-Week Low Club

JetBlue Joins Valeant in Tuesday’s 52-Week Low Club

Valeant Once More Makes Monday’s 52-Week Low Club

Buffett and Top Hedge Funds Continue Massive Insider Buying: Phillips 66, Advanced Auto Parts, Lands’ End, Valeant Pharmaceuticals and More

Valeant, American Airlines Repeat in Friday’s 52-Week Low Club

Valeant, American Airlines, Cavium in Thursday’s 52-Week Low Club

7 Biopharma Companies That Destroyed Shareholders Last Week

Do Analysts See an Inflection Point in Valeant Pharmaceuticals After Earnings?

The 52-Week Low Club for Tuesday

Why Earnings Were Not the Biggest Disappointment in Valeant’s Report

The 3 Most Important Earnings of the Coming Week

Capital Infusions Are More Evidence of a Biotech Turnaround

Did Valeant Pharmaceuticals Capitulate Its Pricing?

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

“Did you buy It from the mob?”: Dave Ramsey hosts floored by 21-year-old’s 30% truck loan

Featured Reads

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan